Articles tagged with Prostaglandin
Researchers at the University of Warwick have identified TRPM2 as a direct pain transducer that amplifies chronic pain signals. Blocking TRPM2 with a drug injected into the joint completely reversed arthritis pain in mice, providing a promising new approach to treating chronic pain more effectively.
Research found that common anti-inflammatory drugs taken by children can alter the formation of dental enamel, leading to defects. The study's authors suggest potential harm from widespread use of these medications and plan to conduct a clinical trial to confirm findings in humans.
Researchers at Linköping University identified the brain cells necessary for a fever reaction in mice, finding that prostaglandin production in these cells is both necessary and sufficient for triggering a fever response. This breakthrough sheds light on the body's defense mechanism against infection and inflammation.
Researchers at Trinity College Dublin have identified a new molecule called 4-OI that can limit the production of prostaglandins from macrophages. This discovery could lead to the development of new anti-inflammatory compounds for treating diseases such as COVID-19 and sleeping sickness.
Researchers at Stanford University School of Medicine discovered that blocking a single protein restores mass and strength to withered muscles in old mice. The protein, 15-PGDH, is elevated in old muscle and its inhibition leads to improved prostaglandin E2 levels, resulting in muscle fiber growth and increased mitochondrial density.
Researchers at McLean Hospital identified two molecules naturally produced by the body that stimulate dopamine production, which may help reverse Parkinson's disease progression. Prostaglandin A1 and E1 protect dopamine-producing neurons from dying and increase dopamine levels without side effects.
Researchers at MUSC found that inhibiting prostaglandin production with indomethacin increases immune cells and reduces tumor burden in premalignant lesions. This activation of the immune system reduces the progression of lesions to HNSCC.
Researchers have discovered that newly introduced populations of the invasive seaweed Gracilaria vermiculophylla in North America and Europe contain significantly higher levels of toxic compounds, including Prostaglandin. This increase in toxicity poses a risk for food safety and may lead to more frequent cases of human intoxication.
A Vanderbilt University Medical Center study found that COX-2 drugs may cause cardiovascular problems due to prostaglandin production by macrophages. The researchers hope to develop new, targeted painkillers without the vascular effects of existing medications.
Fever is triggered by prostaglandin signaling substance produced in the brain's blood vessels. A new study confirms this origin, shedding light on inflammation symptoms and potential drug targets.
Researchers at Lomonosov Moscow State University and Pittsburgh University have identified a new biosynthetic pathway for lipid mediators, producing molecules that regulate inflammation and cell death. The study's findings could lead to the development of new anti-inflammatory drugs.
Researchers have discovered a potential new therapy for influenza by targeting the prostaglandin E2 (PGE2) molecule. This molecule is found to play a crucial role in antiviral immunity and is inhibited by a compound that increases survival rates in mice infected with the H1N1 flu virus.
Researchers found that prostaglandin E2 presence determines stem cell fate, with more present becoming liver cells and less becoming pancreas cells. The discovery could lead to easier generation of liver and pancreas cells for lab research and future therapies.
Researchers found that genetic loss of a proton pump in beta-intercalated cells leads to increased prostaglandin E2 production, promoting hypokalemia and hypercalcemia. Pharmacologic inactivation also results in dRTA-like symptom development.
Scientists discovered that a prostaglandin called PGD2 and its derivative inhibit hair growth, targeting GPR44 as a promising therapeutic target for androgenetic alopecia. Elevated PGD2 levels were found in the bald scalp tissue of men with male pattern baldness.
A new trial suggests that a Foley catheter is as successful in inducing labor as the widely used hormone-like gel prostaglandin E2, but with lower rates of infection and complications. The study found similar vaginal delivery rates and reduced risks of caesarean section, operative deliveries for fetal distress, and neonatal admissions.
A York University study discovered that the drug misoprostol interferes with neuronal cell communication by increasing calcium ions, which reduces cell extensions and prevents cells from communicating. This finding may have implications for understanding neurodevelopmental defects associated with autism.
Researchers at McMaster University have identified a chemical, prostaglandin D2, that may trigger remission in patients with ulcerative colitis. Elevated levels of this chemical were found in patients in long-term remission, suggesting it as a key factor in preventing new episodes.
Children with treatment-resistant bedwetting have higher levels of sodium and urea in their nighttime urine, suggesting an imbalance of prostaglandin hormone-like substance. Researchers found that these imbalances lead to polyuria and enuresis, shedding light on the physiological mechanisms behind this condition.
Research suggests that omega-3 fatty acids in fish oil lower prostaglandin levels by competing with omega-6 fatty acids for the COX enzyme. This reduces inflammation and promotes cardiovascular health. Omega-3s also have less active prostaglandins, contributing to their anti-inflammatory benefits.
A new study by Vanderbilt researchers has uncovered a crucial role for prostaglandins in early embryonic development, highlighting their potential as molecular targets for cancer prevention therapies. Prostaglandin inhibition led to gastrulation arrest and slowed cell movement in zebrafish embryos.
Researchers discovered a connection between iNOS and COX-2 pathways, enabling the development of new anti-inflammatory agents. Drugs that block these bindings may reduce side effects of COX-2 inhibitors, offering a safer form of therapy.
A new method predicts the risk of emergency caesarean section for women attempting a vaginal birth after a previous caesarean section. The method takes into account several factors, including maternal age and sex of the baby, to identify those at low risk of complications.
Researchers discovered that prostaglandin PGD2 has protective effects in the brain, potentially outweighing its negative consequences. The study suggests that targeting this prostaglandin may lead to new therapeutic approaches for conditions involving brain damage, such as stroke and Parkinson's disease.
The event honored Dr. Steven Almo, Dr. Sunney I. Chan, Dr. Ronald W. Davis, Dr. Pehr A. B. Harbury, and Dr. Robert J. Lefkowitz for their outstanding contributions to biochemical and molecular biological research. Dr. William L. Smith also received the ASBMB-Avanti Award in Lipids.
A five-year study demonstrated Xalatan's efficacy in managing open-angle glaucoma by reducing intraocular pressure (IOP) sustainably. The treatment was well-tolerated, controlling IOP without surgery in 72% of patients.
Researchers investigated post-transcriptional regulation of COX2 in tumor cells. They found that microRNA-21 plays a crucial role in modulating COX2 expression by targeting its mRNA for degradation.
A study published in the Proceedings of the National Academy of Sciences found that prostaglandins are required for efficient liver regeneration. The research used mouse models to show that blocking prostaglandin synthesis impaired the liver's regenerative response, highlighting a crucial role for these molecules in liver disease.
Women with a prior cesarean section who deliver by labor have a higher risk of uterine rupture compared to those who opt for another C-section. The study also found that use of prostaglandin to induce labor significantly increases the risk of uterine rupture.
Researchers found that pregnant women who received a hormone-like gel called prostaglandin E2 gave birth faster than those who received a placebo, with an average labor time of 5.6 hours versus 8.6 hours. The study suggests that this gel may help prevent the need for induced labor and reduce Caesarean sections in women at risk